Compass Pathways Bet Everything on Psilocybin Actually Working. The Data Just Said It Does.

There's a specific kind of pharmaceutical bet that only pays off if you're right about something most of the industry spent decades assuming was too risky to touch. Compass Pathways made that bet on psilocybin — the active compound in what most people would just call magic mushrooms — as a treatment for depression that doesn't respond to anything else. This summer, the data came back, and it looks like the company was right.

The headline result is a two-for-two on Phase 3 trials, which in drug development terms is about as close to "proven" as a therapy gets before regulators sign off. COMP005 hit its primary endpoint with high statistical significance in June 2025. COMP006 repeated the feat in February 2026. Two independent, large-scale trials landing on the same result isn't luck — it's the kind of replication the FDA specifically looks for before taking a genuinely novel compound seriously.

But the number that mattered most didn't come until July 7 of this year, and it's the one that answers the question skeptics have been asking about psychedelic therapy since the concept resurfaced in serious medical research: does it actually last? A single supervised dosing session sounds compelling in theory, but plenty of treatments show a short-term bump that fades within weeks. Compass's 26-week durability data confirmed COMP006's effects held through at least six months post-treatment — durability that traditional antidepressants, taken daily for years, often struggle to match.

None of this happened in a regulatory vacuum, and it's worth being honest about why the timeline compressed as fast as it did. In April 2026, President Trump signed an executive order specifically directing the FDA and DEA to accelerate psychedelic drug development for serious mental illness — a genuinely unusual level of White House attention to a single drug category. Six days later, Compass received a Commissioner's National Priority Voucher, a designation that shrinks the FDA's review window to just one to two months once a complete New Drug Application is submitted. Compass is targeting full NDA submission in Q4 2026, which — if the voucher works as designed — puts an actual approval decision within realistic reach by late this year or early next.

It's worth remembering how recently this looked like a much harder road. In 2024, the FDA rejected Lykos Therapeutics' MDMA-based PTSD treatment outright, citing problems with study design and how effectively researchers could actually blind participants to whether they'd received the real drug or a placebo — a genuinely hard methodological problem when the drug itself produces an unmistakable subjective experience. The FDA has since finalized formal clinical trial guidance addressing exactly that blinding problem, and it's scheduled a public hearing on September 14 — four days from now — specifically on the future therapeutic use of psychedelic drugs. Compass isn't operating in the same regulatory fog Lykos was. It's operating in a system that's been rebuilt, in real time, partly because of what went wrong with Lykos's rejection.

Whether COMP360 clears the finish line on the timeline Compass is targeting is still genuinely uncertain — plenty of promising Phase 3 data has stalled at the FDA's final approval stage before. But the case study here isn't really about one company's stock price. It's about how quickly a compound that spent sixty years classified as a Schedule I drug with "no accepted medical use" went from fringe research to a rolling FDA review with a compressed timeline and a specific voucher designed to get it to patients faster. That's a genuinely remarkable regulatory arc, and Compass is the company that's currently furthest along it.